BioCryst Pharmaceuticals (BCRX) soars 16.4% in premarket trading after reporting favorable...

|About: BioCryst Pharmaceuticals,... (BCRX)|By:, SA News Editor

BioCryst Pharmaceuticals (BCRX) soars 16.4% in premarket trading after reporting favorable results on testing of its hepatitis C treatment BCX5191. The preclinical study showed that BCX5191 demonstrates high oral bioavailability and is actively transported into the liver.